DexCom (NASDAQ:DXCM) Now Covered by Analysts at Mizuho

Mizuho assumed coverage on shares of DexCom (NASDAQ:DXCM - Free Report) in a research report released on Thursday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $85.00 target price on the medical device company's stock.

A number of other equities analysts have also issued reports on DXCM. Canaccord Genuity Group boosted their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Citigroup lifted their target price on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.00.

Remove Ads

DexCom Stock Up 2.0 %

NASDAQ:DXCM traded up $1.33 during trading hours on Thursday, hitting $68.72. 2,004,681 shares of the company's stock traded hands, compared to its average volume of 4,185,357. The stock's fifty day moving average price is $76.49 and its two-hundred day moving average price is $76.68. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $26.95 billion, a P/E ratio of 48.06, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom has a twelve month low of $57.52 and a twelve month high of $139.24.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts expect that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc bought a new position in shares of DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. bought a new position in shares of DexCom in the fourth quarter valued at about $33,000. TD Private Client Wealth LLC lifted its stake in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the last quarter. Finally, Larson Financial Group LLC lifted its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.